Infant acute lymphoblastic leukemia : treatment strategies and new insights
Acute lymphoblastic leukemia (ALL) in infants, especially KMT2A gene rearranged ALL (KMT2A-rALL), is a rare disease. Its prognosis is extremely poor, with a reported long-term event-free survival rate of ≤50%. In addition, acute and late toxicities caused by intensive treatment remain issues to be resolved. In the context of this background, the introduction of a more appropriate stratification and a novel treatment with minimal toxicities are urgently required. Establishment of evidence-based novel treatment strategies through an international collaborative study is important owing to the rarity of the disease. Currently, an international collaborative study with a European study group, which includes blinatumomab combined therapy, has been proposed. We herein review previous key clinical trials and the latest treatment strategies for infant ALL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Rinsho ketsueki] The Japanese journal of clinical hematology - 62(2021), 11 vom: 07., Seite 1567-1575 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Miyamura, Takako [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical trial |
|---|
| Anmerkungen: |
Date Completed 07.12.2021 Date Revised 14.12.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.11406/rinketsu.62.1567 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334027993 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334027993 | ||
| 003 | DE-627 | ||
| 005 | 20231225222846.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.11406/rinketsu.62.1567 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM334027993 | ||
| 035 | |a (NLM)34866078 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Miyamura, Takako |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Infant acute lymphoblastic leukemia |b treatment strategies and new insights |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Acute lymphoblastic leukemia (ALL) in infants, especially KMT2A gene rearranged ALL (KMT2A-rALL), is a rare disease. Its prognosis is extremely poor, with a reported long-term event-free survival rate of ≤50%. In addition, acute and late toxicities caused by intensive treatment remain issues to be resolved. In the context of this background, the introduction of a more appropriate stratification and a novel treatment with minimal toxicities are urgently required. Establishment of evidence-based novel treatment strategies through an international collaborative study is important owing to the rarity of the disease. Currently, an international collaborative study with a European study group, which includes blinatumomab combined therapy, has been proposed. We herein review previous key clinical trials and the latest treatment strategies for infant ALL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Infant ALL | |
| 650 | 4 | |a International collaborative study | |
| 650 | 4 | |a KMT2A gene rearrangement | |
| 700 | 1 | |a Tomizawa, Daisuke |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rinsho ketsueki] The Japanese journal of clinical hematology |d 1972 |g 62(2021), 11 vom: 07., Seite 1567-1575 |w (DE-627)NLM000222178 |x 0485-1439 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2021 |g number:11 |g day:07 |g pages:1567-1575 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.11406/rinketsu.62.1567 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2021 |e 11 |b 07 |h 1567-1575 | ||